https://www.youtube.com/watch?v=420W3Y9XisQ

DEFEAT DEGENERATION

 

Neurodegenerative diseases are one of the largest medical challenges of our time. Denali Therapeutics is dedicated to defeating neurodegenerative diseases through rigorous therapeutic discovery and development.

ABOUT US

 

Denali was founded by scientists, drug developers and investors who share the vision that recent scientific insights in genetics, biology and translational medicine offer an unprecedented opportunity to discover and develop effective medicines for patients suffering from neurodegenerative disease.

More about us.

THE TIME IS RIGHT

 

Recent groundbreaking scientific insights into the genetic causes and biological processes underlying neurodegenerative diseases offer an unprecedented opportunity for the discovery and development of effective medicines for Alzheimer’s disease, Parkinson’s disease, ALS and other neurodegenerative diseases.

PATHWAY POTENTIAL

Advances in the genetics, pathology and cell biology underlying chronic neurodegenerative disease have identified pathways that trigger neurodegeneration and contribute to disease onset and progression. Denali is applying deep scientific and drug development expertise to fully harvest the potential of these pathways in order to discover effective molecular therapeutics.

Discover our science.

FOUNDING INVESTORS

Founding investors in Denali’s Series A financing include ARCH Venture Partners, F-Prime Biosciences, Flagship Pioneering as well as the Alaska Permanent Fund. Baillie Gifford, a UK based mutual fund, led Denali’s Series B financing and was joined by several other major institutional investors, sovereign wealth funds and private investors.

JOIN US

 

Discover and develop therapies at Denali.

Current open positions

 

 

 

© 2017 Denali Therapeutics Inc. | 151 Oyster Point Blvd – South San Francisco, CA 94080 | contact@dnli.com

Privacy Policy | Terms of Use